Abstract Library

#4332 Efficacy of SIRT radioembolisation of liver metastases of neuroendocrine tumours (NETs): A single institution experience

Introduction: Majority of NET patients develop liver metastases (NET-LM). Improved treatment of NET-LM may prolong survival. In case of liver-dominant metastatic disease, local radionuclide treatment using microspheres could be considered.

Conference:

Presenting Author: Kropinska A

Authors: Kropinska A, Gola M, Sygula A, Hamm M, Ledwon A,

Keywords: SIRT, radioembolisation, neuroendocrine tumour, liver metastasis,

#3932 Artisan: Prospective phase II trial of TheraSphere Selective Internal Radiation Therapy (SIRT) for liver metastases in neuroendocrine tumors (NETs)

Introduction: The liver is the commonest site of metastases and is an independent predictor of poor outcome. SIRT allows delivery of high dose radiation to liver metastases and has shown promise in the management of NETs. We determined the safety and efficacy of SIRT in those with inoperable liver metastases in a prospective study.

Conference:

Presenting Author: Ahmed Q

Authors: Ahmed Q, Doumanoglou N, Evans J, Martinez M, Ward C,

Keywords: radioembolization, carcinoid, neuroendocrine, metastases,

#3556 Radioembolization of neuroendocrine neoplasms liver metastases: Efficacy and toxicity

Introduction: In patients with unresectable liver metastases, radioembolization has been used to treat tumors from a range of cancers, including neuroendocrine neoplasms.

Conference:

Presenting Author:

Authors: Gola M, Syguła A, Szynkiewicz J, Olczyk T, Kalemba M,

Keywords: radioemolisation liver metastasis,

#3396 Dose-response relationship after yttrium-90-radioembolization with glass microspheres in patients with neuro-endocrine tumor liver metastases

Introduction: In radioembolization, response is achieved through the irradiation and damaging of tumor DNA, while treatment toxicity is mainly related to healthy liver dose. Therefore, optimizing the dose in tumors while minimizing the healthy liver dose is deemed important. However, for hepatic metastases of neuroendocrine tumors, a dose-response relationship has not been established yet.

Conference:

Presenting Author: Ebbers S

Authors: Ebbers S, van Roekel C, Braat M, Barentsz M, Lam M,

Keywords: dose-response, neuroendocrine neoplasm, SIRT, 90y, radioembolization, liver metastasis,

#3353 Severe gastroduodenal ulceration following radioactive microspheres treatment in a woman with metastatic neuroendocrine tumor: A case report of paradoxical microsphere migration

Introduction: Incidence of liver metastasis (LM) in advanced NET is high and associated with poor prognosis. SIR-spheres for non-resectable LM in GEP NETs offers symptom regression and survival benefit. Complications are usually local given the SIR-spheres are delivered directly into the hepatic arteries and give off beta emitting radiation. Off target digression of microspheres to other tissues via hepaticoenteric arteries however can result in nearby organ damage.

Conference:

Presenting Author:

Authors: Smith A, Price T, Kitchener M, Trochsler M,

Keywords: SIR-spheres, microspheres, NET,